 Home > Active Ingredient News > Infection > Phase 3 clinical results of the first domestic bivalent HPV vaccine released: 100% prevention of cervical precancerous lesions

Phase 3 clinical results of the first domestic bivalent HPV vaccine released: 100% prevention of cervical precancerous lesions

 Last Update: 2022-09-06
 Source: Internet
 Author: User

Tags

literature circles high school

promethazine pill high

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cervical cancer is the second most common malignancy in women aged 15-44

The research team carried out a multi-center, randomized, double-blind, controlled (hepatitis E vaccine Yikening®) Phase III clinical trial of Xinkening® based on 5 sites across the country.

The results of the final analysis of the 66-month follow-up of the Phase III clinical trial of CINCONYL® showed that in the per-protocol set (PPS) population, the vaccine was effective against HPV type 16 and/or 18 infection-related lesion endpoints (CIN2+ and/or or VIN2+ and/or VaIN2+) protection was 100.

Paper link:National Research Center for Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The Lancet: The first domestic bivalent HPV vaccine Phase 3 clinical results released, 100% prevention of cervical precancerous lesions

09-09

Related Products

Sodium benzoate CAS No.532-32-1

CAS No.: 532-32-1

$1380/MT FOB

Api Powder Ketoconazole 98% Powder KETOCONAZOLE API POWDER

CAS No.: 65277-42-1

Pharmacy Grade

$3-3.2/KG FOB

High Purity Trimethoprim CAS 738-70-5 for Bacterial Infections

CAS No.: 738-70-5

Chemical Grade

$3.5-4/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Phase 3 clinical results of the first domestic bivalent HPV vaccine released: 100% prevention of cervical precancerous lesions

Related Articles

The Lancet: The first domestic bivalent HPV vaccine Phase 3 clinical results released, 100% prevention of cervical precancerous lesions